Peculiarities of studying the effects of pathogen reduction technologies on platelets
2016 (English)In: PROTEOMICS - Clinical Applications, ISSN 1862-8346, E-ISSN 1862-8354, Vol. 10, no 8, 805-815 p.Article, review/survey (Refereed) Published
The transfusion of platelet concentrates (PCs) is mainly used for treatment of thrombocytopenic, trauma or surgery patients. The integrity and safety of these platelet preparations, however, is compromised by the presence of pathogens, such as viruses, bacteria and parasites. The transfer of allogeneic donor leukocytes contaminating PCs can also potentially cause adverse reactions in recipients. These considerations prompted the development and implementation of pathogen reduction technologies (PRT), which are based on chemically induced cross-linking and inactivation of nucleic acids. While the incumbent PRT may provide some protection against transfusion-transmitted infections, they are ineffective against infectious prions and may not inactivate other emerging pathogens. In addition, the safety of PRT concerning platelet viability and function has been questioned in several reports. Recent studies suggest that PRT, such as Intercept, may adversely affect the messenger RNA (mRNA) and microRNA content of platelets, as well as their functional integrity, which may compromise the clinical benefits of PRT. Here, we will discuss about the peculiarities of studying the effects of PRT on platelets, which will need to be taken into account in future studies aimed to characterize further, and polish, the rugged side of this otherwise useful and potentially important approach in transfusion medicine.
Place, publisher, year, edition, pages
WILEY-V C H VERLAG GMBH , 2016. Vol. 10, no 8, 805-815 p.
MicroRNA; Pathogen reduction; Platelet concentrate; Platelet proteomic; Transfusion medicine
IdentifiersURN: urn:nbn:se:liu:diva-132080DOI: 10.1002/prca.201500124ISI: 000383848400006PubMedID: 27095411OAI: oai:DiVA.org:liu-132080DiVA: diva2:1038391
Funding Agencies|County Council of Ostergotland, Sweden [LIO-202231, LIO-203061]; Canadian Blood Services/Canadian Institutes of Health Research Blood Utilization and Conservation Initiatives via Health Canada [286777, 327364]2016-10-182016-10-172016-10-18